Health care Biotechnology

As per available reports about 2 relevant journals, 10 Conferences, 1 workshops are presently dedicated exclusively to Healthcare Biotechnology and about 70 articles are being published on Healthcare Biotechnology.

Healthcare Biotechnology use proteins, enzymes, antibodies and other substances naturally produced in the human body to treat diseases, including genetic disorders. Biotechnology also uses other living organisms - plant and animal cells, bacteria, viruses and yeasts – in the large-scale production of medicines for human use. Biotechnology produces information that is used to alter and improve cell behavior. Many biotech companies specialize in finding ways to deliver and apply biotechnology information to cells to aid in identifying, preventing and treating disease. Representative applications include diagnostic tests that use biotechnology materials to detect the presence or risk of disease such as cancer, genetic diseases or pollution of a cell or material. There are three primary areas in healthcare in which biotechnology is currently being used: medicines (also including advanced therapies such as cell and gene therapy), vaccines and diagnostics.

Healthcare Biotechnology is a new way to lead a disease free, happy and more intelligent human habitat with longevity and high human capabilities, and offers an excellent learning opportunities and get trained the students in the respective field with theoretical and practical understanding of contemporary biology and biotechnology. It also provides employment opportunities in research, marketing and production in the fields like medicine and healthcare, animal husbandry, agriculture and environment industry.

Market Analysis:

The Healthcare Biotechnology market is witnessing tremendous growth owing to the growth in the number of cancer patients globally and government participation and support through funding and corporate investments for cell-based research. However, high prices of advanced cell counting instruments and lack of proper healthcare and research infrastructure in emerging markets are hampering the growth of the global cell counting market to a certain extent. The global market is expected to reach $8.6 Billion by the end of 2020 and is poised to grow at a CAGR of 6.5% to 7.0% during the forecast period (2015 to 2020).